Caplin Point Laboratories Management
Management criteria checks 4/4
Caplin Point Laboratories' CEO is Sridhar Ganesan, appointed in Mar 2015, has a tenure of 9.75 years. total yearly compensation is ₹9.30M, comprised of 95.7% salary and 4.3% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth ₹228.21M. The average tenure of the management team and the board of directors is 8.8 years and 3.5 years respectively.
Key information
Sridhar Ganesan
Chief executive officer
₹9.3m
Total compensation
| CEO salary percentage | 95.7% |
| CEO tenure | 9.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 8.8yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking
Dec 01
₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 31Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50
Sep 12Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764
Aug 11Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50
Aug 10Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings
Jul 12Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹5b |
| Jun 30 2024 | n/a | n/a | ₹5b |
| Mar 31 2024 | ₹9m | ₹9m | ₹5b |
| Dec 31 2023 | n/a | n/a | ₹4b |
| Sep 30 2023 | n/a | n/a | ₹4b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹9m | ₹8m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹3b |
| Jun 30 2022 | n/a | n/a | ₹3b |
| Mar 31 2022 | ₹6m | ₹5m | ₹3b |
| Dec 31 2021 | n/a | n/a | ₹3b |
| Sep 30 2021 | n/a | n/a | ₹3b |
| Jun 30 2021 | n/a | n/a | ₹3b |
| Mar 31 2021 | ₹6m | ₹5m | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹2b |
| Mar 31 2020 | ₹6m | ₹6m | ₹2b |
| Dec 31 2019 | n/a | n/a | ₹2b |
| Sep 30 2019 | n/a | n/a | ₹2b |
| Jun 30 2019 | n/a | n/a | ₹2b |
| Mar 31 2019 | ₹6m | ₹6m | ₹2b |
| Dec 31 2018 | n/a | n/a | ₹2b |
| Sep 30 2018 | n/a | n/a | ₹2b |
| Jun 30 2018 | n/a | n/a | ₹1b |
| Mar 31 2018 | ₹6m | ₹6m | ₹1b |
Compensation vs Market: Sridhar's total compensation ($USD109.46K) is below average for companies of similar size in the Indian market ($USD470.45K).
Compensation vs Earnings: Sridhar's compensation has been consistent with company performance over the past year.
CEO
Sridhar Ganesan (69 yo)
9.8yrs
Tenure
₹9,300,000
Compensation
Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Whole Time Director | 9.8yrs | ₹9.30m | 0.13% ₹ 228.2m | |
| Chief Financial Officer | 8.8yrs | ₹9.10m | 0.020% ₹ 35.1m | |
| Chief Operating Officer | 13.3yrs | ₹1.90m | 11.84% ₹ 20.8b | |
| General Counsel | 2.3yrs | ₹6.50m | no data | |
| Deputy Chief Financial Officer | no data | no data | no data | |
| Head of Marketing - Latam Business | no data | no data | 11.91% ₹ 20.9b | |
| Chief Transformation & Digital Officer | less than a year | no data | no data |
8.8yrs
Average Tenure
Experienced Management: CAPLIPOINT's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Whole Time Director | 10.8yrs | ₹9.30m | 0.13% ₹ 228.2m | |
| Non-Executive Non-Independent Chairman | 34.7yrs | no data | 18.64% ₹ 32.7b | |
| Non-Executive Independent Director | 4.8yrs | ₹140.00k | no data | |
| Non-Executive Independent Director | 2.3yrs | ₹160.00k | no data | |
| Independent Non-Executive Director | 2.3yrs | ₹180.00k | 0.000090% ₹ 158.1k | |
| Independent Director | less than a year | no data | no data |
3.5yrs
Average Tenure
72yo
Average Age
Experienced Board: CAPLIPOINT's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caplin Point Laboratories Limited is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Siddhant Khandekar | ICICIdirect.com |